Compare 10X Genomics Inc (TXG) vs Vanguard Dividend Appreciation Index Fund ETF (VIG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
10X Genomics Inc vs Vanguard Dividend Appreciation Index Fund ETF — how do they compare? 10X Genomics Inc trades at $82 (market cap $10.07B), while Vanguard Dividend Appreciation Index Fund ETF trades at $237.99 (market cap $132.40B). The key difference: Vanguard Dividend Appreciation Index Fund ETF is far larger — about 13.1× 10X Genomics Inc's market cap, and 10X Genomics Inc is more actively traded (5,657,286 versus 1,287,188). Which is the better fit depends on your goals — on Pluang, investors hold 10X Genomics Inc for 92 Days and Vanguard Dividend Appreciation Index Fund ETF for 133 Days on average.
| TXG | VIG | |
|---|---|---|
Market Cap | $10.07B | $132.40B |
Volume | 5,657,286 | 1,287,188 |
Sector | Health | — |
52-Week High | $97.74 | $246.61 |
52-Week Low | $11.48 | $210.70 |
Typical Hold Time | 92 Days | 133 Days |
Enterprise Value | $9.59B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TXG trades at $76.10, down 5.65% on the day, reflecting a bearish technical trend. The company reported revenue of $642.82M for 2025 with a net loss of $43.54M, though it has consistently beaten quarterly EPS estimates. Recent news highlights strong demand for its Atera spatial biology platform and a patent victory. The stock faces resistance near $77 and support at $72.
The outlook is mixed; strong product demand and improving margins offer upside, but persistent losses and high valuation ratios pose risks. Analyst consensus is divided, with a $74.30 price target slightly below the current price, indicating cautious optimism amid execution challenges.
VIG trades at $236.99, down 0.32% on the day, with a bullish technical signal from moving averages. The ETF focuses on dividend growth companies with at least 10 consecutive years of dividend increases, offering a lower yield but stronger growth profile compared to peers. Recent quarterly dividend increased 7.5%, though year-to-date growth remains modest at 3.3%.
Outlook remains positive for long-term investors seeking dividend growth, with VIG averaging 10% annual returns since inception. Key risks include slower dividend growth pace and exclusion of high-yield stocks by design. The ETF's quality focus provides defensive characteristics but may lag during strong growth markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →About Vanguard Dividend Appreciation Index Fund ETF
The advisor employs an indexing investment approach designed to track the performance of the index, which consists of common stocks of companies that have a record of increasing dividends over time. The advisor attempts to replicate the target index by investing all, or substantially all, of its assets in the stocks that make up the index, holding each stock in approximately the same proportion as its weighting in the index.
Read more on VIG →
